arrow
J

Jeffrey E. Gershenwald

the university of texas-md anderson cancer center
H指数:102
被引数:5.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
Germline variants in cancer susceptibility genes among patients with mucosal melanoma

黏膜黑色素瘤患者中癌症易感基因的生殖系变异

2026-05-230
OAAI
Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection

更正:接受新辅助免疫疗法和淋巴结清扫的临床N1期黑色素瘤患者的真实世界结局

2026-04-240
OAAI
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection

接受新辅助免疫疗法和淋巴结清扫的临床上淋巴结阳性黑色素瘤患者的真实世界结局

2026-03-160
OAAI
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort

病理反应新辅助评分的更新的全肿瘤指南: SITC和INMC的联合努力

2025-11-040
PRE
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma

淋巴细胞清除、肿瘤浸润淋巴细胞,以及高剂量与低剂量IL-2后给予pembrolizumab在转移性黑色素瘤患者中的应用

2025-08-150
OA
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma

原发性皮肤黑色素瘤患者哨兵淋巴结阳性风险预测工具的全球适用性

2025-06-010
PRE
Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis

黑色素瘤脑转移患者总体生存相关的分子和临床特征的综合分析

2025-04-150
OA
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

皮肤黑色素瘤:ESMO 临床实践指南(用于诊断、治疗和随访)

2025-01-0111
PRE
Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort

更新后的泛肿瘤新辅助治疗病理反应评分指南:SITC 与 INMC 联合努力

2024-09-010
PRE
Peripheral CD38+effector memory (EM) T cells are dynamic biomarkers of response to neoadjuvant immune checkpoint blockade (NeoICB) in patients (pts) with resectable dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS)
2024-03-220
PRE
Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma
2024-03-220
PRE
A single dose of perioperative cefazolin disrupts the gut microbiome and immunity in patients (pts) with early-stage melanoma
2024-03-220
PRE
Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes
2023-11-012
OAAI
Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA)
2023-10-072
OA
Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma
2023-10-017
OA
Cutaneous melanoma

皮肤黑色素瘤

LANCET
IF88.5
2023-08-01174
PRE
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy)

黑色素瘤的观点: 黑色素瘤桥会议报告 (2022年12月1至3日-意大利那不勒斯)

2023-07-282
OAAI